On September 19, Menarini Silicon Biosystems announced the launch of new cloud-based data analysis solution, MSBiosuite. MSBiosuite automated data analysis platform processes NGS data generated from research in liquid biopsy area and formalin-fixed paraffin embedded (FFPE) tissue analysis.

Smith & Nephew has been a major player in orthopedics & sports medicine. They pioneered advanced wound care products. However, evolving market trends relating to revenue sources of its clients (i.e. hospitals, trauma centers, & orthopedic clinics) as well as changing healthcare dynamics has provided them with unique opportunity to expand into adjacent market segments such as integrated healthcare solutions and digital surgical platforms. Leveraging their core competency in assisting hospitals/other providers to offer effective surgical outcomes coupled with their unique product portfolio; Smith & Nephew is looking to effectively harness the market potential of integrated and digital health solutions by strategic acquisition of start-ups/emerging players with novel technologies such as Atracsys sarl (July 2019) and BrainLab (June 2019).

On May 28 Lunit Inc. announced an abstract presentation of its AI precision medicine research portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2019. The accepted abstract highlights the feasibility of AI-based biomarker in metastatic non-small cell lung cancer, based on the H&E analysis that predicts response to immune checkpoint inhibitors (ICI).

Danaher Corporation has entered into a definitive agreement with General Electric (GE) Company to acquire a very lucrative Biopharma business unit of GE Life Sciences. Biopharma unit of GE Life Sciences, is the leading provider of instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. The business comprises process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and service.

On Dec 13, 2018 AstraZeneca, a global research based biopharmaceutical company, partnered with Guardant Health (US) for the development of CDx tests to commercialize AstraZeneca’s oncology portfolio including Tagrisso and Imfinzi. The CDx test is based on liquid biopsy platform supported by Guardant’s proprietary Digital Sequencing technology.